Janie reports:
**************************************************


Tom Hale  questions efficacy of
domperidone and says that there is no mechanism by  which it should work.
This leaves us with a drug of questionable efficacy  and potential risk.  To
dismiss this warning out of hand is dangerous  and unprofessional.


***************************************************

Janie, could you please point me to where Tom says this?  I just  looked up
Domperidone in the 2004 edition of Meds & Mothers' Milk,  (p259-260) and among
a heap of other things, he says, "It is also known to  produce significant
increases in prolactin levels and has proven useful as a  galactogogue.  He then
goes on to cite the study by da Silva, rates the  drug as a Lactation Risk
Category L1, and then says under pediatric  concerns:  None reported.  Considered
the ideal galactogogue."


So I'm a bit puzzled as to your statement.  Of course, it is always  possible
that I missed something somewhere along the line.

Could you please let me know where to find your information?  It's  really
important that we have, as you say, all our ducks in a row on this  issue.

Jan Barger, RN, MA, IBCLC
Wheaton  IL
www.lactationeducationconsultants.com

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html